Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo

被引：0
|
作者：
Kirsten Dettmar
Isabell Seitz-Merwald
Carsten Lindemann
Petra Schroeder
Diane Seimetz
Judith Atz
机构：
[1] Fresenius Biotech GmbH,
[2] EUFETS GmbH,undefined
来源：
Clinical and Translational Oncology | 2012年 / 14卷
关键词：
Catumaxomab; Trifunctional antibody; T lymphocyte; Endothelium; Adhesion; Redistributi;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：376 / 381
页数：5
相关论文
共 50 条
  • [1] Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo
    Dettmar, Kirsten
    Seitz-Merwald, Isabell
    Lindemann, Carsten
    Schroeder, Petra
    Seimetz, Diane
    Atz, Judith
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (05): : 376 - 381
  • [2] ROLE OF CATUMAXOMAB (ANTI-EpCAM AND ANTI-CD3) IN OVARIAN CANCER
    Chekerov, Radoslav
    Oskay-Ozcelik, Gulten
    Lichtenegger, Wertner
    Schouli, Jalid
    IUBMB LIFE, 2009, 61 (03) : 293 - 293
  • [3] Different mechanisms of action contribute to the cytotoxic efficacy of catumaxomab (anti-EpCAM x anti-CD3) in vitro
    Lindemann, Carsten
    Schroeder, Petra
    Atz, Judith
    Dettmar, Kirsten
    Kluge, Michael
    CANCER RESEARCH, 2009, 69
  • [4] Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
    Seimetz, Diane
    Lindhofer, Horst
    Bokemeyer, Carsten
    CANCER TREATMENT REVIEWS, 2010, 36 (06) : 458 - 467
  • [5] CONTRIBUTION OF IMMUNOGENIC CELL DEATH (ICD) TO THE ANTI-TUMOR ACTIVITY OF CATUMAXOMAB (ANTI-EPCAM X ANTI-CD3)
    Goere, D.
    Flament, C.
    Chaput-Gras, N.
    Zitvogel, L.
    ANNALS OF ONCOLOGY, 2012, 23 : 169 - 170
  • [6] First Surgical Experience of Intraperitoneal Treatment with the Trifunctional Antibody Catumaxomab (Anti-EpCam x Anti-CD3) for Epithelial Ovarian Cancer
    Papanikolaou, Georgios
    Fotopoulou, Christina
    Braicu, Ioana
    Chekerov, Radoslav
    Schmidt, Sven Christian
    Pietzner, Klaus
    Sehouli, Jalid
    ANTICANCER RESEARCH, 2011, 31 (08) : 2603 - 2608
  • [7] Intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3) for the treatment of peritoneal carcinomatosis due to GI cancer: Results of a phase I trial
    Stroehlein, M.
    Lordick, F.
    Ruettinger, D.
    Gruetzner, U.
    Menzel, H.
    Bartelheim, K.
    Jaeger, M.
    Lindhofer, H.
    Jauch, K.
    Heiss, M. M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 186 - 187
  • [8] Randomised phase II trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
    Knoedler, Maren
    Koerfer, Justus
    Kunzmann, Volker
    Trojan, Joerg
    Daum, Severin
    Schenk, Michael
    Kullmann, Frank
    Schroll, Sebastian
    Behringer, Dirk
    Stahl, Michael
    Al-Batran, Salah-Eddin
    Hacker, Ulrich
    Ibach, Stefan
    Lindhofer, Horst
    Lordick, Florian
    BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 296 - 302
  • [9] Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinoma prior to gastrectomy
    Knoedler, M.
    Koerfer, J.
    Kunzmann, V.
    Trojan, J.
    Daum, S.
    Schenk, M.
    Kullmann, F.
    Schroll, S.
    Behringer, D.
    Stahl, M.
    Al-Batran, S. -E.
    Hacker, U.
    Lordick, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 158 - 158
  • [10] Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM x Anti-CD3) Results of a Phase 1/2 Study
    Sebastian, Martin
    Kiewe, Philipp
    Schuette, Wolfgang
    Brust, Daniel
    Peschel, Christian
    Schneller, Folker
    Ruehle, Karl-Heinz
    Nilius, Georg
    Ewert, Ralf
    Lodziewski, Sven
    Passlick, Bernward
    Siene, Wulf
    Wiewrodt, Rainer
    Jaeger, Michael
    Lindhofer, Horst
    Friccus-Quecke, Hilke
    Schmittel, Alexander
    JOURNAL OF IMMUNOTHERAPY, 2009, 32 (02) : 195 - 202
12345